Another micro-cap biotech has flunked a pivotal test for a regenerative cell therapy – Endpoints News
Endpoints NewsToday the failure belongs to Cytori Therapeutics $CYTX which says that the cells it extracted from patients’ fat failed to hit either the primary or secondary endpoints in a Phase III comparison with placebo in treating scleroderma. Most of the … and more …read more Source:: MicroCap Stock News From Google News
from WordPress http://ift.tt/2gX6h1k
via IFTTT
from WordPress http://ift.tt/2gX6h1k
via IFTTT
Post A Comment
No comments :